Pulmonx Corporation (LUNG) News

Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024

CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference

REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a...

Form 4 - Statement of changes in beneficial ownership of securities

Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Pulmonx Reports Second Quarter 2024 Financial Results

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the...

Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference

REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a...

Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities